If you regularly took Zantac or a generic ranitidine heartburn medication and were later diagnosed with cancer, you may qualify for compensation.
Zantac and its generic equivalent, ranitidine, were among the most widely used heartburn and acid-reflux medications in the world for decades. In 2019, independent lab testing found that ranitidine can break down — especially with age or improper storage — into NDMA, a chemical classified as a probable human carcinogen. The FDA requested a full market withdrawal of all ranitidine products in April 2020.
Lawsuits allege that the companies that manufactured and sold Zantac and generic ranitidine knew or should have known about the NDMA risk and failed to warn consumers, and that regular, long-term use of the drug has been linked to bladder, stomach, esophageal, liver, and pancreatic cancers, among others.
Here's what happens after you reach out:
A short set of free eligibility questions about your situation — takes about two minutes.
Our network reviews your answers against current qualifying criteria and reaches out if you may qualify.
You decide whether to move forward. There's never a cost to check your eligibility.
Zantac litigation has played out across both federal and state courts, and the picture varies significantly by manufacturer and venue. GSK resolved roughly 93% of its pending U.S. state-court claims — about 80,000 plaintiffs — in a $2.2 billion settlement announced in 2024. Separately, in April 2026 a Delaware court dismissed more than 80,000 cases against Boehringer Ingelheim filed before December 2025, after the Delaware Supreme Court tightened the standard for the scientific expert testimony plaintiffs need to prove causation. Cases against other manufacturers, including Pfizer and Sanofi, remain active in state courts including Illinois and California. Because eligibility depends heavily on which product a person used and where a claim is filed, an individual review is the only reliable way to know where a specific case stands.
No. That ruling applied to a specific manufacturer and a specific state court, and other manufacturers and other state courts are still handling Zantac claims. Which brand or generic version you used, and where a claim would be filed, both affect your options — an eligibility review can sort out whether your situation is still viable.
A Delaware court dismissed more than 80,000 Zantac cancer lawsuits against Boehringer Ingelheim in April 2026 over expert testimony standards — but cases against other manufacturers, and in other states, are still moving forward.
Read more →Get updates on Zantac, plus other case types we cover.
We'll keep you updated on Zantac and other case types.